Suppr超能文献

新型嘌呤连接的1,2,3-三唑衍生物作为有效的抗癌剂:设计、合成、对接、密度泛函理论及药物代谢动力学-药物毒性学研究

Novel purine-linked 1,2,3-triazole derivatives as effective anticancer agents: design, synthesis, docking, DFT, and ADME-T investigations.

作者信息

Shaik Khaja Mohiddin, Pandurangan Komala, Allaka Tejeswara Rao, Nalla Seshadri, Ganta Srinivas, Ahmed Mohammad Z, Venkatesan Srinivasadesikan, Kishore Pilli Veera Venkata Nanda

机构信息

Department of Chemistry, School of Applied Sciences, REVA University, Bengaluru, 560064, Karnataka, India.

Centre for Chemical Sciences and Technology, University College of Engineering Science and Technology Hyderabad, Jawaharlal Nehru Technological University Hyderabad, Hyderabad, 500085, Telangana, India.

出版信息

Sci Rep. 2025 Jul 23;15(1):26853. doi: 10.1038/s41598-025-95669-5.

Abstract

The elaboration of a new family of purine molecules bearing triazole-acetamide units is presented. The structure assigned to such molecules was verified by various techniques, including FT-IR, NMR (H/C), and HRMS analysis. The anticancer activity of the resulting compounds was evaluated in vitro against human lung cancer A549, cervical cancer HeLa, and colorectal cancer HCT116 cell lines. Some of the compounds were much more effective than the standard drug doxorubicin (DXN). Toxicity assessments using a healthy cell line indicated that most compounds displayed some level of toxicity, with only a few exceptions. Notably, compounds 5a, 5b, 5e, 5i, and 5j, unveiled significant cytotoxicity, resulting in notable inhibitory concentrations in cell survival against A549 (IC = 4.02 - 15.34 µM), HeLa (6.02-22.12 µM), and HCT116 (6.11 - 22.57 µM) at a concentration of 10 µM. Based on the results, the synthesized compounds 5e, 5a, and 5d were able to inhibit A549 cell line by IC of 4.02 ± 0.11, 5.20 ± 0.32, and 12.34 ± 0.25 µM, respectively. Additionally, the molecular docking approach was employed to correlate the in vitro anticancer inhibitory activity well with the in-silico study, and the result obtained corroborated that active analogues established several key interactions at positions Ala(A), Ile(A), Gly(A), Cys(A), Leu(A), Arg(A), Asn(A), Thr(A) with the active site of the lung cancer protein (PDB: 1 × 2 J). To further understand, the DFT studies have been explored. The results analysis revealed crucial information about the structure, electronic properties, and reactivity of these triazole scaffolds and identified the best inhibitor, 5e, in line with experimental observation. The experimental results were supported by molecular docking analysis, reinforcing the validity of the results. Extending our exploration, an analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME-Tox) profiling confirmed the safe use of these newly synthesized compounds, paving the way for promising applications in the medical field.

摘要

本文介绍了一类带有三唑-乙酰胺单元的新型嘌呤分子。通过多种技术(包括傅里叶变换红外光谱(FT-IR)、核磁共振(H/C)和高分辨率质谱(HRMS)分析)对这类分子的结构进行了验证。对所得化合物的抗癌活性进行了体外评估,针对人肺癌A549、宫颈癌HeLa和结直肠癌HCT116细胞系。其中一些化合物比标准药物阿霉素(DXN)更有效。使用健康细胞系进行的毒性评估表明,大多数化合物表现出一定程度的毒性,只有少数例外。值得注意的是,化合物5a、5b、5e、5i和5j表现出显著的细胞毒性,在10μM浓度下,对A549(IC = 4.02 - 15.34μM)、HeLa(6.02 - 22.12μM)和HCT116(6.11 - 22.57μM)细胞存活的抑制浓度显著。基于这些结果,合成的化合物5e、5a和5d分别能够以4.02±0.11、5.20±0.32和12.34±0.25μM的IC抑制A549细胞系。此外,采用分子对接方法将体外抗癌抑制活性与计算机模拟研究很好地关联起来,所得结果证实活性类似物在丙氨酸(A)、异亮氨酸(A)、甘氨酸(A)、半胱氨酸(A)、亮氨酸(A)、精氨酸(A)、天冬酰胺(A)、苏氨酸(A)位置与肺癌蛋白的活性位点(蛋白质数据银行:1×2J)建立了几个关键相互作用。为了进一步了解,还进行了密度泛函理论(DFT)研究。结果分析揭示了有关这些三唑支架的结构、电子性质和反应性的关键信息,并根据实验观察确定了最佳抑制剂5e。分子对接分析支持了实验结果,加强了结果的有效性。进一步拓展我们的探索,对吸收、分布、代谢、排泄和毒性(ADME-Tox)特征的分析证实了这些新合成化合物的安全使用,为在医学领域的有前景应用铺平了道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8729/12287522/5cfc11b122e5/41598_2025_95669_Sch1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验